EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Romosozumab‐Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease

Jose Luis Diaz Macip iD, Izabela Turcu, Jyothsna Goranti, Sreeja Sivaguru, Sai Priyanka Kodam, Zeeshan Afzal

ACR Open Rheumatology · 2026-04 · 8 (4)

DOI: 10.1002/acr2.90054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 14.04.2026. Verfasst von Jose Luis Diaz Macip und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to describe recurrent erythema nodosum (EN) temporally associated with romosozumab in a patient with mixed connective tissue disease and to examine the biologic plausibility of this association in the context of Wnt/β‐catenin–mediated immune regulation.

Methods

We evaluated a patient with mixed connective tissue disease and osteoporosis who developed EN following romosozumab exposure. Clinical assessment included detailed medication reconciliation, infectious evaluation, markers of inflammation, response to glucocorticoids, and recurrence upon re‐exposure. A focused literature review was conducted to assess prior reports and mechanistic relevance.

Results

A 71‐year‐old woman developed EN approximately one month after her first dose of romosozumab, with complete remission following prednisone therapy. Within days of the second dose, she experienced a more extensive recurrence involving the hands, thighs, and right calf, which resolved after a glucocorticoid taper. Infectious evaluation was negative, markers of inflammation were normal, and medication reconciliation did not identify alternative pharmacologic triggers. Romosozumab was discontinued, and no recurrence occurred during follow‐up before transition to denosumab.

Conclusion

This case supports a probable association between romosozumab and recurrent EN. Rechallenge, exclusion of alternative etiologies, and emerging evidence on Wnt‐mediated immune regulation suggest a mechanistic link between sclerostin inhibition and panniculitic hypersensitivity reactions.

Autor:innen und Institutionen

  • Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso.
  • Division of Rheumatology, University of Nevada, Las Vegas.
  • Division of Rheumatology, Texas Tech University Health Sciences Center El Paso.

ORCID-Profile: Jose Luis Diaz Macip

Zitieren

APA

Diaz Macip, J. L., Turcu, I., Goranti, J., Sivaguru, S., Kodam, S. P., & Afzal, Z. (2026). Romosozumab‐Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease. ACR Open Rheumatology, 8(4). https://doi.org/10.1002/acr2.90054

Vancouver

Diaz Macip JL, Turcu I, Goranti J, Sivaguru S, Kodam SP, Afzal Z. Romosozumab‐Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease. ACR Open Rheumatology. 2026;8(4). doi:10.1002/acr2.90054

BibTeX
@article{DiazMacip2026,
  author = {Diaz Macip, Jose Luis and Turcu, Izabela and Goranti, Jyothsna and Sivaguru, Sreeja and Kodam, Sai Priyanka and Afzal, Zeeshan},
  title = {Romosozumab‐Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.1002/acr2.90054}
}
Kostenlos starten →